NAGE Q3 2018 Earnings — Niagen Bioscience Inc Revenue & Financial Results | Market Cap Arena

NAGENiagen Bioscience Inc

$393M

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M+33.5% YoY

Gross Profit

$4M53.7% margin

Operating Income

-$9M-105.9% margin

Net Income

-$9M-106.0% margin

EPS (Diluted)

$-0.16

QoQ Revenue Growth

+4.1%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$47M

Total Liabilities

$14M

Stockholders' Equity

$33M

Cash & Equivalents

$28M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$6M	+33.5%
Gross Profit	$4M	$3M	+49.6%
Operating Income	-$9M	-$3M	-170.7%
Net Income	-$9M	$2M	-502.7%